Skip to Main Content

Paper Details

Patient-derived Models of Abiraterone- and Enzalutamide-resistant Prostate Cancer Reveal Sensitivity to Ribosome-directed Therapy.
Eur Urol
79
2018
AR, AR gene, AR mutations, Abiraterone, Abiraterone- and Enzalutamide-resistant Prostate Cancer, BET, CDK4/6, CRPC, CX-5461, CX-6258, Enzalutamide, JQ1, Ki67, PARP, PARTICIPANTS, PATIENT, PDX culture system, PDX tissues, PDXs, PIM kinase, Patient, RNA polymerase I, androgen, androgen receptor, antitumour, cancer, cancer cells, castration-resistant prostate cancer, cisplatin, cleaved caspase-3, enzalutamide, ex vivo, galeterone, iBET151, patient, patient-derived xenografts, patients, prostate cancers, ribociclib, talazoparib, tumour
Author NameAffiliation
Mitchell G LawrenceMonash Biomedicine Discovery Institute Cancer Program, Monash University, Peter MacCallum Cancer Centre
Luke A SelthDame Roma Mitchell Cancer Research Laboratories and Freemasons Foundation Centre for Men's Health, Adelaide Medical School, University of Adelaide
Richard J RebelloMonash Biomedicine Discovery Institute Cancer Program, Monash University, Peter MacCallum Cancer Centre
Melissa PapargirisMonash Biomedicine Discovery Institute Cancer Program, Monash University
Arun A AzadSchool of Clinical Sciences, Monash University
Damien BoltonAustin Hospital, The University of Melbourne
Declan G MurphyThe University of Melbourne, Peter MacCallum Cancer Centre
Heather ThornePeter MacCallum Cancer Centre, The University of Melbourne
David Clouston
Richard B PearsonPeter MacCallum Cancer Centre, The University of Melbourne, Monash University, University of Melbourne
Mark FrydenbergMonash Biomedicine Discovery Institute Cancer Program, Monash University
Renea A TaylorPeter MacCallum Cancer Centre, Monash Biomedicine Discovery Institute Cancer Program, Monash University
Gail P RisbridgerMonash Biomedicine Discovery Institute Cancer Program, Monash University, Peter MacCallum Cancer Centre, The University of Melbourne
  • 1 - 13

Datasets

Release 1.2